Information Provided By: 
Fly News Breaks for March 3, 2020
OMER
Mar 3, 2020 | 07:11 EDT
Cantor Fitzgerald analyst Brandon Folkes believes Omeros shares "could significantly rerate from current levels." The "strong" Narsoplimab data unlock significant long-term value for investors, Folkes tells investors in a research note. The analyst's due diligence suggests investors can be rewarded from current levels through the pipeline alone. As such, he believes the stock's risk/reward is to the upside, "creating a compelling investment opportunity." Folkes keeps an Overweight rating on Omeros with a $26 price target.
News For OMER From the Last 2 Days
There are no results for your query OMER
